Cargando…
Synergistic antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 when combined with anti-PD-1 in murine tumor models
Autores principales: | Murali, Addepalli, Langowski, John L, Rhoneil, Pena, Jha, Priyam, Charych, Deborah H, Doberstein, Stephen K, Hoch, Ute |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649417/ http://dx.doi.org/10.1186/2051-1426-3-S2-P231 |
Ejemplares similares
-
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
por: Charych, Deborah, et al.
Publicado: (2017) -
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer
por: Walker, Joshua M, et al.
Publicado: (2020) -
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
por: Miyazaki, Takahiro, et al.
Publicado: (2021) -
Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
por: Hennessy, Marlene, et al.
Publicado: (2020) -
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
por: Adkins, Chris E., et al.
Publicado: (2015)